Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Barry A. Chioza is active.

Publication


Featured researches published by Barry A. Chioza.


The EMBO Journal | 2013

Deficiency of terminal ADP‐ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease

Reza Sharifi; Rosa Morra; C. Denise Appel; Michael Tallis; Barry A. Chioza; Gytis Jankevicius; Michael A. Simpson; Ivan Matic; Ege Ozkan; Barbara Golia; Matthew J. Schellenberg; Ria Weston; Jason G. Williams; Marianna N Rossi; Hamid Galehdari; Juno M. Krahn; Alexander Wan; Richard C. Trembath; Andrew H. Crosby; Dragana Ahel; Ronald T. Hay; Andreas G. Ladurner; Gyula Timinszky; R. Scott Williams; Ivan Ahel

Adenosine diphosphate (ADP)‐ribosylation is a post‐translational protein modification implicated in the regulation of a range of cellular processes. A family of proteins that catalyse ADP‐ribosylation reactions are the poly(ADP‐ribose) (PAR) polymerases (PARPs). PARPs covalently attach an ADP‐ribose nucleotide to target proteins and some PARP family members can subsequently add additional ADP‐ribose units to generate a PAR chain. The hydrolysis of PAR chains is catalysed by PAR glycohydrolase (PARG). PARG is unable to cleave the mono(ADP‐ribose) unit directly linked to the protein and although the enzymatic activity that catalyses this reaction has been detected in mammalian cell extracts, the protein(s) responsible remain unknown. Here, we report the homozygous mutation of the c6orf130 gene in patients with severe neurodegeneration, and identify C6orf130 as a PARP‐interacting protein that removes mono(ADP‐ribosyl)ation on glutamate amino acid residues in PARP‐modified proteins. X‐ray structures and biochemical analysis of C6orf130 suggest a mechanism of catalytic reversal involving a transient C6orf130 lysyl‐(ADP‐ribose) intermediate. Furthermore, depletion of C6orf130 protein in cells leads to proliferation and DNA repair defects. Collectively, our data suggest that C6orf130 enzymatic activity has a role in the turnover and recycling of protein ADP‐ribosylation, and we have implicated the importance of this protein in supporting normal cellular function in humans.


American Journal of Human Genetics | 2010

Defective mitochondrial mRNA maturation is associated with spastic ataxia.

Andrew H. Crosby; Heema Patel; Barry A. Chioza; Christos Proukakis; Kay Gurtz; Michael A. Patton; Reza Sharifi; Gaurav V. Harlalka; Michael A. Simpson; Katherine J. Dick; Johanna A. Reed; Ali Al-Memar; Zofia M.A. Chrzanowska-Lightowlers; Harold E. Cross; Robert N. Lightowlers

In human mitochondria, polyadenylation of mRNA, undertaken by the nuclear-encoded mitochondrial poly(A) RNA polymerase, is essential for maintaining mitochondrial gene expression. Our molecular investigation of an autosomal-recessive spastic ataxia with optic atrophy, present among the Old Order Amish, identified a mutation of MTPAP associated with the disease phenotype. When subjected to poly(A) tail-length assays, mitochondrial mRNAs from affected individuals were shown to have severely truncated poly(A) tails. Although defective mitochondrial DNA maintenance underlies a well-described group of clinical disorders, our findings reveal a defect of mitochondrial mRNA maturation associated with human disease and imply that this disease mechanism should be considered in other complex neurodegenerative disorders.


American Journal of Human Genetics | 2012

Defective Presynaptic Choline Transport Underlies Hereditary Motor Neuropathy

Katy E.S. Barwick; Jane Wright; Saeed Al-Turki; Meriel McEntagart; Ajith Nair; Barry A. Chioza; Ali Al-Memar; Hamid Modarres; Mary M. Reilly; Katherine J. Dick; Alicia M. Ruggiero; Randy D. Blakely; Andrew H. Crosby

The neuromuscular junction (NMJ) is a specialized synapse with a complex molecular architecture that provides for reliable transmission between the nerve terminal and muscle fiber. Using linkage analysis and whole-exome sequencing of DNA samples from subjects with distal hereditary motor neuropathy type VII, we identified a mutation in SLC5A7, which encodes the presynaptic choline transporter (CHT), a critical determinant of synaptic acetylcholine synthesis and release at the NMJ. This dominantly segregating SLC5A7 mutation truncates the encoded product just beyond the final transmembrane domain, eliminating cytosolic-C-terminus sequences known to regulate surface transporter trafficking. Choline-transport assays in both transfected cells and monocytes from affected individuals revealed significant reductions in hemicholinium-3-sensitive choline uptake, a finding consistent with a dominant-negative mode of action. The discovery of CHT dysfunction underlying motor neuropathy identifies a biological basis for this group of conditions and widens the spectrum of disorders that derive from impaired NMJ transmission. Our findings compel consideration of mutations in SLC5A7 or its functional partners in relation to unexplained motor neuronopathies.


Nature Genetics | 2015

A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome

Vafa Alakbarzade; Abdul Hameed; Debra Q.Y. Quek; Barry A. Chioza; Emma L. Baple; Amaury Cazenave-Gassiot; Long N. Nguyen; Markus R. Wenk; Arshia Q Ahmad; Ajith Sreekantan-Nair; Michael N. Weedon; Phil Rich; Michael A. Patton; Thomas T. Warner; David L. Silver; Andrew H. Crosby

The major pathway by which the brain obtains essential omega-3 fatty acids from the circulation is through a sodium-dependent lysophosphatidylcholine (LPC) transporter (MFSD2A), expressed in the endothelium of the blood-brain barrier. Here we show that a homozygous mutation affecting a highly conserved MFSD2A residue (p.Ser339Leu) is associated with a progressive microcephaly syndrome characterized by intellectual disability, spasticity and absent speech. We show that the p.Ser339Leu alteration does not affect protein or cell surface expression but rather significantly reduces, although not completely abolishes, transporter activity. Notably, affected individuals displayed significantly increased plasma concentrations of LPCs containing mono- and polyunsaturated fatty acyl chains, indicative of reduced brain uptake, confirming the specificity of MFSD2A for LPCs having mono- and polyunsaturated fatty acyl chains. Together, these findings indicate an essential role for LPCs in human brain development and function and provide the first description of disease associated with aberrant brain LPC transport in humans.


Brain | 2013

Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis

Gaurav V. Harlalka; Anna Lehman; Barry A. Chioza; Emma L. Baple; Reza Maroofian; Harold E. Cross; Ajith Sreekantan-Nair; David A. Priestman; Saeed Al-Turki; Meriel McEntagart; Christos Proukakis; Louise Royle; Radoslaw P. Kozak; Laila Bastaki; Michael A. Patton; K. Wagner; Roselyn Coblentz; Joy Price; Michelle M. Mezei; Kamilla Schlade-Bartusiak; Frances M. Platt; Andrew H. Crosby

Glycosphingolipids are ubiquitous constituents of eukaryotic plasma membranes, and their sialylated derivatives, gangliosides, are the major class of glycoconjugates expressed by neurons. Deficiencies in their catabolic pathways give rise to a large and well-studied group of inherited disorders, the lysosomal storage diseases. Although many glycosphingolipid catabolic defects have been defined, only one proven inherited disease arising from a defect in ganglioside biosynthesis is known. This disease, because of defects in the first step of ganglioside biosynthesis (GM3 synthase), results in a severe epileptic disorder found at high frequency amongst the Old Order Amish. Here we investigated an unusual neurodegenerative phenotype, most commonly classified as a complex form of hereditary spastic paraplegia, present in families from Kuwait, Italy and the Old Order Amish. Our genetic studies identified mutations in B4GALNT1 (GM2 synthase), encoding the enzyme that catalyzes the second step in complex ganglioside biosynthesis, as the cause of this neurodegenerative phenotype. Biochemical profiling of glycosphingolipid biosynthesis confirmed a lack of GM2 in affected subjects in association with a predictable increase in levels of its precursor, GM3, a finding that will greatly facilitate diagnosis of this condition. With the description of two neurological human diseases involving defects in two sequentially acting enzymes in ganglioside biosynthesis, there is the real possibility that a previously unidentified family of ganglioside deficiency diseases exist. The study of patients and animal models of these disorders will pave the way for a greater understanding of the role gangliosides play in neuronal structure and function and provide insights into the development of effective treatment therapies.


Journal of Clinical Investigation | 2014

Hypomorphic PCNA mutation underlies a human DNA repair disorder

Emma L. Baple; Helen Chambers; Harold E. Cross; Heather Fawcett; Yuka Nakazawa; Barry A. Chioza; Gaurav V. Harlalka; Sahar Mansour; Ajith Sreekantan-Nair; Michael A. Patton; Martina Muggenthaler; Phillip Rich; K. Wagner; Roselyn Coblentz; Constance K. Stein; A. Malcolm R. Taylor; Andrew P. Jackson; Tomoo Ogi; Alan R. Lehmann; Catherine M. Green; Andrew H. Crosby

Numerous human disorders, including Cockayne syndrome, UV-sensitive syndrome, xeroderma pigmentosum, and trichothiodystrophy, result from the mutation of genes encoding molecules important for nucleotide excision repair. Here, we describe a syndrome in which the cardinal clinical features include short stature, hearing loss, premature aging, telangiectasia, neurodegeneration, and photosensitivity, resulting from a homozygous missense (p.Ser228Ile) sequence alteration of the proliferating cell nuclear antigen (PCNA). PCNA is a highly conserved sliding clamp protein essential for DNA replication and repair. Due to this fundamental role, mutations in PCNA that profoundly impair protein function would be incompatible with life. Interestingly, while the p.Ser228Ile alteration appeared to have no effect on protein levels or DNA replication, patient cells exhibited marked abnormalities in response to UV irradiation, displaying substantial reductions in both UV survival and RNA synthesis recovery. The p.Ser228Ile change also profoundly altered PCNAs interaction with Flap endonuclease 1 and DNA Ligase 1, DNA metabolism enzymes. Together, our findings detail a mutation of PCNA in humans associated with a neurodegenerative phenotype, displaying clinical and molecular features common to other DNA repair disorders, which we showed to be attributable to a hypomorphic amino acid alteration.


Journal of Medical Genetics | 2013

Mutation of HERC2 causes developmental delay with Angelman-like features

Gaurav V. Harlalka; Emma L. Baple; Harold E. Cross; Simone Kühnle; Monica Cubillos-Rojas; Konstantin Matentzoglu; Michael A. Patton; K. Wagner; Roselyn Coblentz; Debra L Ford; Deborah J.G. Mackay; Barry A. Chioza; Martin Scheffner; Jose Luis Rosa; Andrew H. Crosby

Background Deregulation of the activity of the ubiquitin ligase E6AP (UBE3A) is well recognised to contribute to the development of Angelman syndrome (AS). The ubiquitin ligase HERC2, encoded by the HERC2 gene is thought to be a key regulator of E6AP. Methods and results Using a combination of autozygosity mapping and linkage analysis, we studied an autosomal-recessive neurodevelopmental disorder with some phenotypic similarities to AS, found among the Old Order Amish. Our molecular investigation identified a mutation in HERC2 associated with the disease phenotype. We establish that the encoded mutant HERC2 protein has a reduced half-life compared with its wild-type counterpart, which is associated with a significant reduction in HERC2 levels in affected individuals. Conclusions Our data implicate a model in which disruption of HERC2 function relates to a reduction in E6AP activity resulting in neurodevelopmental delay, suggesting a previously unrecognised role of HERC2 in the pathogenesis of AS.


Journal of Clinical Investigation | 2013

SLITRK6 mutations cause myopia and deafness in humans and mice

Mustafa Tekin; Barry A. Chioza; Yoshifumi Matsumoto; Oscar Diaz-Horta; Harold E. Cross; Duygu Duman; Haris Kokotas; Heather L. Moore-Barton; Kazuto Sakoori; Maya Ota; Yuri S. Odaka; Joseph Foster; F. Basak Cengiz; Suna Tokgoz-Yilmaz; Oya Tekeli; Maria Grigoriadou; Michael B. Petersen; Ajith Sreekantan-Nair; Kay Gurtz; Xia Juan Xia; Arti Pandya; Michael A. Patton; Juan I. Young; Jun Aruga; Andrew H. Crosby

Myopia is by far the most common human eye disorder that is known to have a clear, albeit poorly defined, heritable component. In this study, we describe an autosomal-recessive syndrome characterized by high myopia and sensorineural deafness. Our molecular investigation in 3 families led to the identification of 3 homozygous nonsense mutations (p.R181X, p.S297X, and p.Q414X) in SLIT and NTRK-like family, member 6 (SLITRK6), a leucine-rich repeat domain transmembrane protein. All 3 mutant SLITRK6 proteins displayed defective cell surface localization. High-resolution MRI of WT and Slitrk6-deficient mouse eyes revealed axial length increase in the mutant (the endophenotype of myopia). Additionally, mutant mice exhibited auditory function deficits that mirrored the human phenotype. Histological investigation of WT and Slitrk6-deficient mouse retinas in postnatal development indicated a delay in synaptogenesis in Slitrk6-deficient animals. Taken together, our results showed that SLITRK6 plays a crucial role in the development of normal hearing as well as vision in humans and in mice and that its disruption leads to a syndrome characterized by severe myopia and deafness.


Brain | 2017

PRUNE is crucial for normal brain development and mutated in microcephaly with neurodevelopmental impairment

Massimo Zollo; Mustafa Y. Ahmed; Veronica Ferrucci; Vincenzo Salpietro; Fatemeh Asadzadeh; Marianeve Carotenuto; Reza Maroofian; Ahmed Al-Amri; Royana Singh; Iolanda Scognamiglio; Majid Mojarrad; Luca Musella; Angela Duilio; Angela Di Somma; Ender Karaca; Anna Rajab; Aisha Al-Khayat; Tribhuvan Mohan Mohapatra; Atieh Eslahi; Farah Ashrafzadeh; Lettie E. Rawlins; Rajniti Prasad; Rashmi Gupta; Preeti Kumari; Mona Srivastava; Flora Cozzolino; Sunil Kumar Rai; Maria Chiara Monti; Gaurav V. Harlalka; Michael A. Simpson

Zollo et al. report that mutations in PRUNE1, a phosphoesterase superfamily molecule, underlie primary microcephaly and profound global developmental delay in four unrelated families from Oman, India, Iran and Italy. The study highlights a potential role for prune during microtubule polymerization, suggesting that prune syndrome may be a tubulinopathy.


Brain | 2015

Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73

Robert N. Jinks; Erik G. Puffenberger; Emma L. Baple; Brian Harding; Peter B. Crino; Agnes B. Fogo; Olivia Wenger; Baozhong Xin; Alanna E. Koehler; Madeleine McGlincy; Margaret M. Provencher; Jeffrey D. Smith; Linh K. Tran; Saeed Al Turki; Barry A. Chioza; Harold E. Cross; Gaurav V. Harlalka; Reza Maroofian; Adam D. Heaps; Mary C. Morton; Lisa M. Stempak; Friedhelm Hildebrandt; Carolin E. Sadowski; Joshua J. Zaritsky; Kenneth Geno Campellone; D. Holmes Morton; Heng Wang; Andrew H. Crosby; Kevin A. Strauss

Galloway-Mowat syndrome (GMS) is a neurodevelopmental disorder characterized by microcephaly, cerebellar hypoplasia, nephrosis, and profound intellectual disability. Jinks et al. extend the GMS spectrum by identifying a novel nephrocerebellar syndrome with selective striatal cholinergic interneuron loss and complete lateral geniculate nucleus delamination, caused by a frameshift mutation in WDR73.

Collaboration


Dive into the Barry A. Chioza's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge